6Mackenzie-Feder J, Sirrs S, Anderson D, et al. Primary hyperparathy- roidism : an overview. Int J Endocrinol,2011,25 : 1410.
7Marx SJ. Hyperparathyroid and hypoparathyroid disorders. N Engl J Med, 2000,343 : 1863-1875.
8Cetani F, Pardi E, Borsari S, et al. Molecular pathogenesis of primary hyperparathyroidism ,2011,34 ( 7 Suppl) : S35-39.
9Iqbal AA, Burgess EH, Gallina DL, et al. Hypercaleemia in hyperthy- roidism:patterns of serum calcium parathyroid hormone and 1,25-di- hydroxyvitamin D3 levels during management of thyrotoxicosis. Endocr Pract,2003 ,9 :9517-9521.
10Kimura H, Sato K, Nishimaki M, et al. Symptomatic hypercalcemia due to painless thyroiditis after unilateral adrenalectomy in a patient with Cushing' s syndrome. Intern Med ,2008,47:751-756.
二级参考文献14
1Phitayakom R, Mchenry CR. Hyperparathyroid crisis: use of bisphos?phonates as a bridge to parathyroidectomy. J Am CoIl Surg,2008 ,206: 1106-1115.
2Pall an S, Rahman MO, Khan AA. Diagnosis and management of primary hyperparathyroidism. BMJ ,2012 ,344 : e 1 0 13.
3Mundy GR, Edwards JR. PTH-related peptide ( PTHrP) in hypercalce?mia. J Am Soc Nephrol,2008, 19 :672-675.
5Carroll MF, Schade DS. A practical approach to hypercalcemia. Am Fam Physician ,2003,67: 1959-1966.
6Major P , Lortholary A, Hon J ,et a1. Zoledronic acid is superior to pam?idronate in the treatment of hypercalcemia of malignancy: a pooled anal?ysis of two randomized, controlled clinical trials. J Clin Oncol, 2001 , 19:558-567.
7Kawada K, Minami H, Okabe K, et a1. A multicenter and open lahel clinical trial of zoledronic acid 4mg in patients with hypercalcemia of malignancy. Jpn J Clin Oncol,2005 ,35 :28-33.
8Bech A, Smolders K, Telting D, et al. Cinacalcet for hypercalcemia caused by pulmonary squamous cell carcinoma producing parathyroid hormone-related Peptide. Case Rep Oneal ,2012,5: 1-8.
9Stopeck AT, Lipton A, Body JJ, et a1. Denosumab compared with zole?dronic acid for the treatment of bone metastases in patients with ad?vanced breast cancer: a randomized, double-blind study. J Clin Oneal, 2010,28 :5132-5139.
10Clines GA. Mechanisms and treatment of hypercalcemia of malignancy. CUlT Opin Endocrinol Diabetes Obes,20]] ,18 :339-346.
3Martins D,Wolf M,Pan D,et al. Prevalence of cardiovascular riskfactors and the serum levels of 25 -hydroxyvitamin D in the UnitedStates : data from the Third National Health and NutritionExamination Survey [ J]. Arch Intern Med,2007,167 (11) :1159-1165.
4Luo C, Wong J,Brown M,et al. Hypovitaminosis D in Chinese type2 diabetes : lack of impact on clinical metabolic status andbiomarkers of cellular inflammation [ J]. Diab Vksc Dis Res,2009,6(3) :194-199.
5Kositsawat J, Freeman VL, Gerber BS, et al. Association of AlClevels with vitamin D status in U. S. adults : data from the NationalHealth and Nutrition Examination Survey [ J]. Diabetes Care,2010,33(6) :1236-1238.
6Danescu LG,Levy S,Levy J. Vitamin D and diabetes mellitus [J].Endocrine,2009,35( 1):11-17.
7McGill AT, Stewart JM, Lithander FE,et al. Relationships of lowserum vitamin D3 with anthropometry and markers of the metabolicsyndrome and diabetes in overweight and obesity [J]. Nutr J,2008,7:4.
8Vacek JL,Vanga SR, Good M, et al. Vitamin D deficiency and supple- mentation and relation to cardiovascular health[ J]. Am J Cardio1,2012, 109 ( 3 ) :359-363.
9Vieth R. What is the otimal vitamin D status for health? [ J]. ProgBio- phys Mol Bio1,2006 ,92 :26-32.
10Baz-Hecht M, Goldfine AB. The impact of vitamin D deficiency on dia- betes and cardiovascular risk [ J ]. Curr Opin Endocrinol Diabetes Obes, 2010,17(2) :113-119.
